{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:06:35Z","timestamp":1774566395834,"version":"3.50.1"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2026,2,10]]},"abstract":"<jats:p>Intoxication with novel psychoactive substances, such as the designer benzodiazepine flubromazepam, can be diagnostically challenging. A man in his late 50s presented with a persistently decreased level of consciousness and extensive multifocal intracerebral ischaemia on an MR brain scan. After excluding multiple causes, a toxicology screen identified flubromazepam use as the likely explanation. This novel psychoactive substance has an elimination half-life of 106 hours and life-threatening side effects, including hypotension and sedative-hypnotic toxidrome. Flubromazepam is increasingly used, with a significant risk of serious toxicity. Physicians should consider novel psychoactive substance toxicity in patients with unexplained neurological presentations, particularly with decreased consciousness and multifocal intracerebral ischaemia.<\/jats:p>","DOI":"10.1136\/pn-2025-005012","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:20:28Z","timestamp":1772043628000},"page":"pn-2025-005012","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Flubromazepam intoxication causing prolonged coma and multifocal cerebral ischaemia"],"prefix":"10.1136","author":[{"given":"Lotte","family":"Pitlo","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurosurgery, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ynte M","family":"Ruigrok","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedor E L","family":"Migchelsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Jongstra","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026022510200950000_pn-2025-005012v1.1","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2023-003796"},{"key":"2026022510200950000_pn-2025-005012v1.2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jat\/bkad011","article-title":"Simultaneous Screening and Quantitation of Drugs and Their Metabolites in Postmortem Samples by Liquid Chromatography-High-Resolution Mass Spectrometry: Does It Provide Any Benefits?","volume":"47","author":"Rab","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2026022510200950000_pn-2025-005012v1.3","unstructured":"European Medicine Agency (EMA) . Guideline on bioanalytical method validation. EMEA\/CHMP\/EWP\/192217\/2009. London European Medicines Agency; 2015.1\u201323."},{"key":"2026022510200950000_pn-2025-005012v1.4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","article-title":"Flubromazolam--A new life-threatening designer benzodiazepine","volume":"54","author":"\u0141ukasik-G\u0142\u0119bocka","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"2026022510200950000_pn-2025-005012v1.5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An expanding world of new psychoactive substances-designer benzodiazepines","volume":"73","author":"Zawilska","year":"2019","journal-title":"Neurotoxicology"},{"key":"2026022510200950000_pn-2025-005012v1.6","unstructured":"European Monitoring Centre for Drugs and Drug Addiction . Perspectives on drugs: the misuse of benzodiazepines among high-risk opioid users in Europe. 2018. Available: https:\/\/www.euda.europa.eu\/publications\/pods\/benzodiazepines_en [Accessed 16 Oct 2025]."},{"key":"2026022510200950000_pn-2025-005012v1.7","doi-asserted-by":"crossref","DOI":"10.3390\/ph14060560","article-title":"Designer Benzodiazepines: A Review of Toxicology and Public Health Risks","volume":"14","author":"Brunetti","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026022510200950000_pn-2025-005012v1.8","unstructured":"Dutch Poisons Information Center (DPIC). Utrecht The Netherlands: University Medical Center."},{"key":"2026022510200950000_pn-2025-005012v1.9","doi-asserted-by":"crossref","unstructured":"Koch K , Auw\u00e4rter V , Hermanns-Clausen M , et al . Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. Drug Test Anal 2018. doi:10.1002\/dta.2391","DOI":"10.1002\/dta.2391"},{"key":"2026022510200950000_pn-2025-005012v1.10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/toxres\/tfac039","article-title":"The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents","volume":"11","author":"Hong","year":"2022","journal-title":"Toxicol Res (Camb)"},{"key":"2026022510200950000_pn-2025-005012v1.11","unstructured":"Auw\u00e4rter V , Morais J , Gallegos A , et al . New benzodiazepines in europe\u2014a review. European Monitoring Centre for Drugs and Drug Addiction; 2021. Available: https:\/\/www.euda.europa.eu\/publications\/rapid-communications\/new-benzodiazepines-europe-review_en [Accessed 16 Oct 2025]."},{"key":"2026022510200950000_pn-2025-005012v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3279"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2025-005012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:20:34Z","timestamp":1772043634000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2025-005012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":12,"alternative-id":["10.1136\/pn-2025-005012"],"URL":"https:\/\/doi.org\/10.1136\/pn-2025-005012","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}